Delivery technologies for cancer immunotherapy
Top Cited Papers
- 8 January 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 18 (3), 175-196
- https://doi.org/10.1038/s41573-018-0006-z
Abstract
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding how to increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.Keywords
This publication has 248 references indexed in Scilit:
- Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticlesBiomaterials, 2012
- Endosome maturationThe EMBO Journal, 2011
- Cytokines and the inception of CD8 T cell responsesTrends in Immunology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Therapeutic cell engineering with surface-conjugated synthetic nanoparticlesNature Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Progress and prospects: immune responses to viral vectorsGene Therapy, 2009
- Infection-mimicking materials to program dendritic cells in situNature Materials, 2009
- Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with gliomaNature Clinical Practice Oncology, 2008
- Cancer-related inflammationNature, 2008